Table 1 Recommendations for HCC surveillance
From: Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Condition | AASLD29 | AGA81 | EASL11 | APASL122 |
|---|---|---|---|---|
Cirrhosis | Surveillance recommended in Child–Pugh stages A or B; individuals in Child–Pugh stage C should only undergo surveillance if they are eligible for liver transplantation | None | Surveillance is recommended in Child–Pugh stages A and B; individuals in Child–Pugh stage C should only undergo surveillance if they are awaiting liver transplantation | Surveillance is recommended for individuals with cirrhosis |
Chronic hepatitis B without cirrhosis | Surveillance is recommended for men from endemic countries aged >40 years; women from endemic countries aged >50 years; people from Africa; people with a family history of HCC; people with a PAGE-B score ≥10 | None | Individuals at intermediate or high risk of HCC (PAGE-B score ≥10) | Surveillance is recommended for Asian men aged >40 years, Asian women aged >50 years, Black people aged >20 years and people with a family history of HCC |
Chronic hepatitis C without cirrhosis | Routine surveillance is not recommended | None | Individuals with stage 3 fibrosis may be considered for surveillance | Surveillance is recommended for patients with HCV cure treated with DAAs, regardless of fibrosis stage |
NAFLD without cirrhosis | Routine surveillance is not recommended | Consider surveillance in advanced (stage 3–4) fibrosis | Individuals with stage 3 fibrosis may be considered for surveillance | None |
